FAKTOR-OPTIONSSCHEIN - BIOMERIEUX Stock

Certificat

DE000MG0HV94

Real-time Bid/Ask 04:53:29 2024-05-20 EDT
8.34 EUR / 8.4 EUR +1.45% Intraday chart for FAKTOR-OPTIONSSCHEIN - BIOMERIEUX
Current month-17.00%
1 month-19.20%
Date Price Change
24-05-20 8.37 +1.45%
24-05-17 8.25 +0.24%
24-05-16 8.23 -0.84%
24-05-15 8.3 +2.22%
24-05-14 8.12 -6.34%

Delayed Quote Börse Stuttgart

Last update May 20, 2024 at 03:57 am

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying BIOMÉRIEUX
Issuer Morgan Stanley
WKN MG0HV9
ISINDE000MG0HV94
Date issued 2024-03-20
Strike 71.97
Maturity Unlimited
Parity 2.89 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 13.25
Lowest since issue 8.12
Spread 0.06
Spread %0.71%

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Sector
-
More about the company

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: bioMérieux

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
95.9 EUR
Average target price
113.4 EUR
Spread / Average Target
+18.25%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW